Theravance Biopharma Inc (TBPH)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Theravance Biopharma Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 16.90 $ — 61% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
8 of 10 Growth gemTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 27.9% passed
- More than 10% revenue growth is expected for the coming year 15.1% passed
- Share count grows by less than 3% a year -11.2% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 288.9% passed
- Gross margin at 40% or higher and without meaningful erosion 94.9% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 240 m net cash passed
- Operating cash flow covers the profits of the last three years 206 m passed
- Return on capital at 15% or higher, or up versus two years ago -3.0% failed
- Insiders hold at least 10% or are net buyers 4.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 4.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.21 | 0.21 – 0.21 | 84 | 241.8% | 1 |
| 12/31/2027 | 0.80 | 0.80 – 0.80 | 97 | 281.0% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.14 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.31 | – | 19 | 6.80 | -82.80 | -1 | -1 |
| 2025: Q1 | -0.27 | – | 15 | 6.10 | -88.20 | 43 | 43 |
| 2025: Q2 | 1.08 | – | 26 | 83.70 | 209.30 | 208 | 208 |
| 2025: Q3 | 0.07 | – | 20 | 18.50 | 18.10 | -7 | -7 |
| 2025: Q4 | 1.15 | – | 46 | 144.70 | 133.00 | -6 | -6 |
| 2026: Q1 | -0.10 | – | 18 | 15.00 | -27.90 | 73 | 73 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 49 | -180 | -191 | -4.26 | -99 | 350 | 639 |
| 2017 | 15 | -260 | -285 | -5.45 | -201 | 115 | 441 |
| 2018 | 60 | -239 | -216 | -3.99 | -113 | -52 | 560 |
| 2019 | 73 | -252 | -236 | -4.25 | -238 | -224 | 409 |
| 2020 | 72 | -298 | -278 | -4.46 | -250 | -304 | 469 |
| 2021 | 55 | -258 | -199 | -2.87 | -208 | -339 | 375 |
| 2022 | 51 | -92 | 872 | 11.85 | -187 | 442 | 607 |
| 2023 | 57 | -56 | -55 | -1.00 | -27 | 213 | 382 |
| 2024 | 64 | -47 | -56 | -1.16 | -12 | 176 | 354 |
| 2025 | 107 | -13 | 106 | 2.06 | 239 | 297 | 486 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Theravance Biopharma, Inc., ein biopharmazeutisches Unternehmen, entwickelt und vermarktet Medikamente in den USA.
| Employees | 90 |
|---|---|
| Headquarters | South San Francisco, CA |
| Address | 901 Gateway Boulevard, 94080 South San Francisco, United States |
| Phone | 650 808 6000 |
| Website | theravance.com |
| IPO Date | 16. May 2014 |
| ISIN | KYG8807B1068 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Rick E. Winningham M.B.A. | CEO & Director | 1960 |
| Rhonda F. Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | 1965 |
| Aine Miller Ph.D. | Senior VP of Development & Head of Ireland Office | 1977 |
| Aziz Sawaf C.F.A. | Senior VP of Operations Strategy & CFO | 1982 |
| Stuart Knight | Senior VP of IT&I and Chief Information Officer | – |
| Brett A. Grimaud Esq. | Senior VP, General Counsel & Secretary | 1974 |
| Stacy L. Pryce | Senior VP & Chief Strategy Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 7. Jul 2026 | Samaha Eli | 10% Owner | Sell | 5,564 | 17.17 | 95,541 |
| 6. Jul 2026 | Samaha Eli | 10% Owner | Sell | 1,400 | 17.04 | 23,856 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.